NCT00909090

Macular Pigment and Glare Disability

Effects of Lutein and Zeaxanthin Upon MPOD and Its Effects Upon Glare Disability, Photostress Recovery, and Contrast Enhancement in Healthy Subjects: A Randomized, Double-blind Placebo-controlled Study

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 109 (actual)
• Sponsor: University of Georgia · Academic / Other
• Sex: All
• Age: 18 Years – 40 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is: I. To measure MP optical density (MPOD) in two groups (experimental and placebo) of 50 subjects each (N = 100), during an Lutein + Zeaxanthin supplementation period of 12 months. II. To test the hypothesis that increases in MP (via 12 mg daily Lutein + Zeaxanthin supplementation) will result in significantly improved visual performance under disability glare conditions. III. To test the hypothesis that increases in MP (via 12 mg daily L + Z supplementation) will result in significantly reduced photostress recovery times. IV. To test the hypothesis that increases in MP (via 12 mg daily L + Z supplementation) will result in improved contrast enhancement.

Detailed description

The following measurements will be taken, before and after supplementation with lutein and zeaxanthin: Macular pigment optical density (MPOD) Visual performance under glare conditions Photostress recovery times chromatic contrast sensitivity.

Conditions

• Vision, Entoptic

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	12 mg Lutein + Zeaxanthin	10 mg FloraGlo lutein + 2 mg Optisharp zeaxanthin, taken once daily for one year
DIETARY_SUPPLEMENT	Visually identical placebo	Visually identical placebo, taken once daily for one year

Timeline

• Start date: 2009-05-01
• Primary completion: 2012-12-01
• Completion: 2012-12-01
• First posted: 2009-05-27
• Last updated: 2020-07-13
• Results posted: 2020-07-13

Locations

1 site across 1 country: United States